Combination regimens involving SETD2 inhibitors with WEE1 inhibitors, HDMIs, or PARPis have demonstrated encouraging therapeutic efficacy in preclinical cancer models and are expected to form the basis for new treatment strategies for prostate cancer. The gene discussed is SETD2; the disease is prostate carcinoma.